Managing Oral and Ocular Toxicities in Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss practical strategies for preventing, monitoring, and managing oral and ocular toxicities in patients with metastatic triple-negative breast cancer (mTNBC) receiving antibody-drug conjugate therapy. The faculty emphasize the importance of initiating preventive oral care measures early, including corticosteroid mouth rinses, nonalcoholic mouthwash, saline rinses, dietary modifications, and patient education to reduce the risk and severity of stomatitis. They also review approaches to managing ocular surface events, highlighting the value of baseline ophthalmologic evaluation, prophylactic supportive eye care, and prompt referral to ophthalmology when clinically indicated. NP Zafman explains when dose interruptions or dose reductions may be appropriate for persistent or clinically significant toxicities, while NP Stukus reinforces the importance of setting patient expectations before treatment begins. Together, the speakers underscore that early recognition, preventive supportive care, and multidisciplinary collaboration are essential to maintaining treatment continuity and preserving quality of life for patients with metastatic triple-negative breast cancer.